TY - JOUR T1 - Concomitant latent tuberculosis in patients with lung cancer JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P2627 AU - Wei-Juin Su AU - Wen-Chien Fan AU - Jia-Yih Feng AU - Shiang-Fen Huang Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P2627.abstract N2 - Background: Tuberculosis (TB) appears to be a risk factor for lung cancer, but whether or not it is the cause is still uncertain. Patients with latent TB infection (LTBI) are vulnerable to develop active TB, however, the relationship between lung cancer and LTBI is not well understood.Methods: We conducted a prospective study of 340 newly diagnosed lung cancer patients from four medical centers in Taiwan. LTBI was detected by using QuantiFERON-TB Gold In-Tube (QFT-GIT) assay. Demographic data and cancer-related factors associated with LTBI were investigated. The survival status was also analyzed according to the status of LTBI.Results: Of 340 lung cancer patients, LTBI was detected in 96 (28.2%), and 30 (8.8%) showed indeterminate results of QFT-GIT. Non-adenocarcinoma cases had higher proportion of LTBI than those of adenocarcinoma, especially in patients with younger age. In multivariate analysis, COPD (OR 2.41, 95% CI 1.25-4.64), fibrocalcified lesions on chest radiogram (OR 2.73, 95% CI 1.45-5.11), and tumor growth in areas common for TB (OR 2.02, 95% CI 1.15-3.55) were independent clinical predictors for LTBI. In multivariate analysis, independent predictors for one-year all-cause mortality included BMI <18.5 (HR 2.09, 95% CI 1.06-4.14, p=0.033), advanced stage of lung cancer (RR 7.76, 95% CI 1.90-31.78, p=0.004), and indeterminate QFT-GIT results (RR 2.40, 95% CI 1.27-4.54, p=0.007).Conclusions: The results suggest that LTBI is common among lung cancer patients in Taiwan. Co-existence of COPD, fibrocalcified lesions on chest radiogram, and tumor growth in areas common for TB are associated with LTBI. However, indeterminate QFT-GIT result was an independent predictor for all-cause mortality in lung cancer patients. ER -